Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 227

recruiting
3 987
countries
28
conditions
2 109

4 491 trials match your criteria

Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled

Crohn's disease

Not recruiting

Study on Guselkumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab

Plasma cell myeloma

Not recruiting

Study on the Safety and Effectiveness of Motixafortide and G-CSF for Stem Cell Collection in Patients with Multiple Myeloma

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Motixafortide

Angelman's syndrome

Not recruiting

Study on the Long-Term Safety of GTX-102 for Patients with Angelman Syndrome

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Apazunersen

Parkinson's disease

Not recruiting

Study on the Effects and Safety of Prasinezumab for Patients with Early Parkinson's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab

Neoplasm

Not recruiting

Study of RVU120 for Patients with Advanced Solid Tumors After Standard Treatments Have Failed

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride

Porphyria non-acute

Not recruiting

Study on the Safety and Tolerability of Oral Dersimelagon for Patients with Erythropoietic Protoporphyria or X-Linked Protoporphyria

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dersimelagon Phosphate

Study Comparing Lazertinib and Subcutaneous Amivantamab with Intravenous Amivantamab for Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Prostate cancer

Not recruiting

Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide

Lupus nephritis

Not recruiting

Study on the Effects of Ianalumab with Standard Therapy for Patients with Active Lupus Nephritis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine

Neoplasm

Not recruiting

Study on Repotrectinib for Patients with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Gene Changes

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Repotrectinib

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ofatumumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.